

Appl. No. 09/623,138
Amdt. dated July 31, 2003
Reply to Office action of April 3, 2003

Amendments to the Claims

This listing of claims will replace all prior versions,
and listings, of claims in the application.

Listing of Claims:

Claims 1-10 (canceled).

Gl
Claim 11 (currently amended) A method for
inhibiting ocular Langerhans cell migration in a mammal
comprising administering an effective amount of a
Langerhans cell migration inhibitor comprising a compound
selected from calcitriol; $1\alpha,24$ -dihydroxy vitamin D_3 ; α -
calcidol; calcifedol; $1\alpha,25,26$ -trihydroxy vitamin D_3 ;
 $1\beta,25$ -dihydroxy vitamin D_3 ; 24-homo- $1\alpha,25$ -dihydroxy
vitamin D_3 ; 26-homo- $1\alpha,25$ -dihydroxy vitamin D_3 ; 22-
oxacalcitol; and calcipotriol as an active ingredient to
the mammal, wherein the inhibition of said ocular
Langerhans cell migration results in the ~~prevention or~~
treatment of keratoconjunctivitis, phlyctenular
keratitis, or corneal infiltration and wherein the
compounds treat the ocular inflammation without lowering
transparency of the cornea.

Claims 12-13 (canceled).

Appl. No. 09/623,138
Amdt. dated July 31, 2003
Reply to Office action of April 3, 2003

Claim 14 (previously presented) The method of
Claim 11 wherein the compound is calcitriol or 22-
oxacalcitriol.

61
G
Cont
Claim 15 (previously presented) The method of
Claim 14 wherein the inhibitor is in the form of an
ophthalmic solution.

Claim 16 (canceled)

Claim 17 (currently amended) The method of
Claim 15 wherein the inhibition of the Langerhans cell
migration results in the ~~prevention of~~ treatment of
keratoconjunctivitis.

Claim 18 (canceled).

Claim 19 (previously presented) The method of
Claim 15 wherein the inhibition of the Langerhans cell
migration results in the prevention or treatment of
phlyctenular keratitis or corneal infiltration.

Claim 20 (currently amended) The method of
Claim 15 wherein the inhibitor prevents and/or treats an
ocular inflammation wherein the inhibition of the

Appl. No. 09/625,138

Amdt. dated July 31, 2003

Reply to Office action of April 3, 2003

*Gr
cont*

Langerhans cell migration results in the ~~prevention or~~
treatment of an ocular inflammation by inhibiting the
production of interleukin-1 in corneal epithelial
cells.
